Home › Compare › JWCTF vs PLD

JWCTF vs PLD: Dividend Comparison 2026

JWCTF yields 651.47% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JWCTF wins by $503571.99M in total portfolio value
10 years
JWCTF
JWCTF
● Live price
651.47%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$503577.90M
Annual income
$386,785,137,245.59
Full JWCTF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — JWCTF vs PLD

📍 JWCTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJWCTFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JWCTF + PLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
JWCTF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JWCTF
Annual income on $10K today (after 15% tax)
$55,374.59/yr
After 10yr DRIP, annual income (after tax)
$328,767,366,658.75/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, JWCTF beats the other by $328,763,328,542.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JWCTF + PLD for your $10,000?

JWCTF: 50%PLD: 50%
100% PLD50/50100% JWCTF
Portfolio after 10yr
$251791.90M
Annual income
$193,394,943,985.38/yr
Blended yield
76.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

JWCTF
No analyst data
Altman Z
-9.3
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JWCTF buys
0
PLD buys
0
No recent congressional trades found for JWCTF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJWCTFPLD
Forward yield651.47% ✓3.10%
Annual dividend / share$2.00$4.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4% ✓
Portfolio after 10y$503577.90M ✓$5.91M
Annual income after 10y$386,785,137,245.59 ✓$4,750,725.19
Total dividends collected$493990.56M ✓$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: JWCTF vs PLD ($10,000, DRIP)

YearJWCTF PortfolioJWCTF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$75,847$65,146.58$11,241$540.96+$64.6K → JWCTF
2$542,945$461,789.28$13,019$991.13+$529.9K → JWCTF
3$3,670,393$3,089,441.65$15,801$1,870.97+$3.65M → JWCTF
4$23,446,108$19,518,787.95$20,609$3,701.21+$23.43M → JWCTF
5$141,614,527$116,527,191.03$29,919$7,867.97+$141.58M → JWCTF
6$809,307,352$657,779,808.21$50,631$18,617.74+$809.26M → JWCTF
7$4,379,155,354$3,513,196,486.95$105,528$51,352.20+$4379.05M → JWCTF
8$22,451,936,399$17,766,240,170.59$287,364$174,449.42+$22451.65M → JWCTF
9$109,152,115,265$85,128,543,318.27$1,081,760$774,280.77+$109151.03M → JWCTF
10$503,577,900,579$386,785,137,245.59$5,908,209$4,750,725.19+$503571.99M → JWCTF

JWCTF vs PLD: Complete Analysis 2026

JWCTF — Stock

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Full JWCTF Calculator →

PLD — REIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this JWCTF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JWCTF vs SCHDJWCTF vs JEPIJWCTF vs OJWCTF vs KOJWCTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.